[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:head-and-neck-squamous-cell-carcinoma:pik3ca-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Head and Neck Squamous Cell Carcinoma","PIK3CA Gene",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06993844","Phase 1\u002F2 Study of ETX-636 in Participants With Advanced Solid Tumors",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:17:23.750999Z","2026-05-05T02:43:27.756864Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05039801","IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors",[20],"Phase 1","2026-08-26T02:18:49.989941Z","2026-04-29T02:57:57.070174Z",{"nct_id":24,"title":25,"phases":26,"status":27,"updated_at":28,"content_modified":29},"NCT06496568","A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T03:39:05.349687Z","2026-05-05T02:43:28.201534Z"]